HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Targeting tyrosine kinases: a novel therapeutic strategy for systemic sclerosis.

AbstractPURPOSE OF REVIEW:
This article reviews the current evidence and rationale for the use of tyrosine kinase inhibitors as potential therapeutic interventions for systemic sclerosis.
RECENT FINDINGS:
The signaling cascades of the profibrotic cytokines transforming growth factor-β and platelet-derived growth factor utilize tyrosine kinases. Preclinical studies have suggested potential efficacy of tyrosine kinase inhibitors in fibrosing disorders. Imatinib, dasatinib, and nilotinib treatment of scleroderma and normal fibroblasts leads to decreased production of extracellular matrix proteins in an in-vitro model. Several murine models demonstrate decreased skin thickening with tyrosine kinase inhibition. Case reports and one open-label trial suggest potential efficacy of imatinib in diffuse systemic sclerosis, although adverse events are common. One controlled and several uncontrolled trials are ongoing, and their results will better define the role of tyrosine kinase inhibition in the treatment of this disorder.
SUMMARY:
Tyrosine kinase inhibition as a potential strategy for the treatment of systemic sclerosis has been gaining more widespread interest based on preclinical data and open-label experiences. Large, multicenter, double-blind, randomized controlled trials are needed to assess the efficacy and safety of this approach in this complex disease.
AuthorsJessica K Gordon, Robert F Spiera
JournalCurrent opinion in rheumatology (Curr Opin Rheumatol) Vol. 22 Issue 6 Pg. 690-5 (Nov 2010) ISSN: 1531-6963 [Electronic] United States
PMID20827202 (Publication Type: Journal Article, Review)
Chemical References
  • Protein Kinase Inhibitors
  • Protein-Tyrosine Kinases
Topics
  • Animals
  • Disease Models, Animal
  • Fibrosis
  • Humans
  • Mice
  • Protein Kinase Inhibitors (pharmacology, therapeutic use)
  • Protein-Tyrosine Kinases (antagonists & inhibitors, metabolism, physiology)
  • Scleroderma, Systemic (drug therapy, enzymology, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: